Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection

Aliment Pharmacol Ther. 2000 Oct;14(10):1339-43. doi: 10.1046/j.1365-2036.2000.00846.x.


Background: One-week low-dose proton pump inhibitor-based triple therapies have usually proved to be effective treatments for Helicobacter pylori infection.

Aim: To investigate the eradication efficacy, safety profile and patient compliance of two triple therapies containing a standard dose of rabeprazole and a new fluoroquinolone, levofloxacin.

Methods: One hundred patients referred to us for gastroscopy, who were H. pylori-positive, were consecutively recruited in a prospective, open-label study. The enrolled patients were randomised to receive a seven-day course of rabeprazole 20 mg o.d. plus levofloxacin 500 mg o.d. and either amoxycillin 1 g b.d. (RLA group) or tinidazole 500 mg b.d. (RLT group). Their H. pylori status was assessed by means of histology and rapid urease test at entry, and by 13C-urea breath test 8 weeks after the end of treatment.

Results: All 100 enrolled patients completed the study. Forty-six of 50 patients treated with RLA (both PP and ITT analysis: 92%; 95% CI: 81-98%) and 45 of 50 with RLT (both PP and ITT analysis: 90%: 95% CI: 78-97%), became H. pylori-negative. Slight or mild side-effects occurred in 4 (8%) patients of the RLA group and in 5 (10%) of the RLT group.

Conclusions: This study demonstrates the efficacy of two 1-week rabeprazole-based triple therapies including levofloxacin to eradicate H. pylori. These regimens prove to be safe, well-tolerated, and achieved good eradication rates. Levofloxacin may be an effective alternative to clarithromycin in triple therapy regimens.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Adolescent
  • Adult
  • Aged
  • Amoxicillin / adverse effects
  • Amoxicillin / therapeutic use*
  • Anti-Infective Agents / adverse effects
  • Anti-Infective Agents / therapeutic use*
  • Anti-Ulcer Agents / adverse effects
  • Anti-Ulcer Agents / therapeutic use*
  • Benzimidazoles / adverse effects
  • Benzimidazoles / therapeutic use*
  • Female
  • Follow-Up Studies
  • Gastric Acid / metabolism
  • Helicobacter Infections / drug therapy*
  • Helicobacter Infections / microbiology
  • Helicobacter pylori*
  • Humans
  • Levofloxacin*
  • Male
  • Middle Aged
  • Ofloxacin / adverse effects
  • Ofloxacin / therapeutic use*
  • Omeprazole / analogs & derivatives
  • Penicillins / adverse effects
  • Penicillins / therapeutic use*
  • Prospective Studies
  • Rabeprazole
  • Tinidazole / adverse effects
  • Tinidazole / therapeutic use*


  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Anti-Infective Agents
  • Anti-Ulcer Agents
  • Benzimidazoles
  • Penicillins
  • Tinidazole
  • Rabeprazole
  • Levofloxacin
  • Amoxicillin
  • Ofloxacin
  • Omeprazole